Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the “Company”) and Phytanix Bio Inc. have entered into a definitive share exchange agreement pursuant to which the two entities will combine in an all-stock transaction (the “Combination”). The combined entity, to be called Phytanix, Inc., will bring together two pipelines focused on stress-related and CNS disorders, five preclinical assets and one clinical-stage asset. “This combination aligns two pipelines with complementary assets and expertise to address unmet needs in neuropsychiatry, CNS and other disorders,” said Garo H. Armen, PhD, Executive Chairman.
Read the full article: Protagenic Therapeutics and Phytanix Announce Business Combination to Form Neuroactive Biopharmaceutical Company //
Source: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/protagenic-therapeutics-and-phytanix-announce-business-combination-to-1029131